PLX - Protalix BioTherapeutics, Inc.
| Previous Close | 0.4500 |
| Open | 0.4500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.4229 - 0.4575 |
| 52 Week Range | 0.4200 - 1.0600 |
| Volume | 327,832 |
| Avg. Volume | 787,391 |
| Market Cap | 64.167M |
| Beta | 1.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6510 |
| Earnings Date | Mar 10, 2016 - Mar 14, 2016 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.55 |
- GlobeNewswire•23 days ago
Research Report Identifies Comtech Telecommunications, Protalix BioTherapeutics, Kraton, ABB, Cheniere Energy Partners LP, and Heidrick & Struggles International with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- ACCESSWIRE•last month
Protalix BioTherapeutics, OPRX-106 Phase II Results, Analysts Review and Target, Catalysts
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
- GlobeNewswire•last month
Protalix BioTherapeutics Announces Acceptance of Abstract on OPRX-106 as a Lecture Presentation at the Digestive Diseases Week® 2018
CARMIEL, Israel, March 19, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its ...
- GlobeNewswire•last month
Protalix BioTherapeutics to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference
CARMIEL, Israel, March 15, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its ...
- Benzinga•last month
Benzinga Pro's 5 Stock To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Athersys, Inc. (NASDAQ: ATHX ) stock gained more than ...
- GlobeNewswire•last month
Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis
Clinical Responses Observed in 67% of Patients and Clinical Remission Observed in 28% of Patients. CARMIEL, Israel, March 13, 2018-- Protalix BioTherapeutics, Inc., announced today, positive results from ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of PLX earnings conference call or presentation 6-Mar-18 1:30pm GMT
Q4 2017 Protalix Biotherapeutics Inc Earnings Call
- GlobeNewswire•last month
Protalix BioTherapeutics Reports 2017 Full Year Results and Provides Corporate Update
Enrollment in all Fabry Trials is ongoing in over Forty Active Sites. Current Cash is Projected to Fund the Company through Clinical Trial Read-Outs and into 2020. CARMIEL, Israel, March 06, 2018-- Protalix ...
- Simply Wall St.•last month
Protalix BioTherapeutics Inc (NYSEMKT:PLX): Are Analysts Optimistic?
Protalix BioTherapeutics Inc’s (AMEX:PLX): Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in IsraelRead More...
- ACCESSWIRE•last month
Protalix Biotherapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 6, 2018 / Protalix Biotherapeutics, Inc. (NYSE American: PLX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 6, 2018, at 8:30 ...
- GlobeNewswire•2 months ago
Protalix BioTherapeutics to Hold Full-Year 2017 Financial Results and Corporate Update Conference Call on March 6, 2018
CARMIEL, Israel, Feb. 26, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary ...
- GlobeNewswire•2 months ago
Protalix BioTherapeutics Announces Final Dosing of Last Patient in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
CARMIEL, Israel, Feb. 15, 2018-- Protalix BioTherapeutics, Inc., announced today the final dosing of the last patient in the Company’ s phase II clinical trial evaluating OPRX-106, the Company’ s oral ...
- GlobeNewswire•3 months ago
Protalix BioTherapeutics’ pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration
CARMIEL, Israel, Jan. 31, 2018--. Protalix BioTherapeutics, Inc., announced that the U.S. Food and Drug Administration has granted Fast Track designation to pegunigalsidase alfa, or PRX-102, the Company’ ...
- GlobeNewswire•3 months ago
Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium™ 2018
CARMIEL, Israel, Jan. 29, 2018-- Protalix BioTherapeutics, Inc., announced today that the Company will participate in the 14 th Annual WORLD Symposium™ 2018 taking place February 5– 8, 2018 at the Manchester ...
- SmarterAnalyst•4 months ago
Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Fly 10% Following Impressive Phase II Interim Data in Ulcerative Colitis
Protalix Biotherapeutics Inc (NYSE:PLX) stock is riding a nearly 10% gain this morning after the Israeli biotech firm unleashed positive interim data from its Phase II clinical study in ulcerative colitis (UC). The trial is investigating the company's oral anti-TNF drug OPRX-106, with data set loose from the first 14 patients who have completed the randomized, open label, two-arm study. A total of 24 patients were enrolled and randomized to receive 2 mg or 8 mg of OPRX-106, administered orally, once daily, for 8 weeks. The first 14 patients have completed the study, and four patients are currently in treatment and follow-up. The trial evaluated key efficacy endpoints including clinical response and remission utilizing the Mayo score, as well as safety and pharmacokinetics.
- ACCESSWIRE•4 months ago
Wired News - Protalix BioTherapeutics Granted Orphan Drug Designation for the Treatment of Fabry Disease
LONDON, UK / ACCESSWIRE / December 29, 2017 / Active-Investors.com has just released a free research report on Protalix BioTherapeutics, Inc. (NYSE: PLX ). If you want access to this report all you need ...
- Zacks•4 months ago
Protalix (PLX) Fabry Disease Candidate Gets Orphan Status
Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.
- SmarterAnalyst•4 months ago
Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Vault Another 7% After PRX-102 Wins Orphan Drug Designation from European Commission
Protalix Biotherapeutics Inc (NYSE:PLX) shares had already been on a solid 3% bump yesterday and in pre-market trading have gone on to race up another close to 7% amid the news of an exciting victory: the Israeli pharma firm's Fabry disease asset PRX-102 gained favor from the European Commission by granting of an Orphan Drug Designation (ODD). Should this orphan drug designation be maintained when the Fabry disease candidate garners approval for marketing in the European Union (EU), this could translate to an advantage of ten years of market exclusivity for Protalix within the EU. For context, the company has designed its PRX-102 asset, or pegunigalsidase alfa, as a plant cell culture expressed, and a chemically modified version of the recombinant alpha-Galactosidase-A protein, aimed to treat Fabry disease that afflicts one person out of every 40,000.
Capital Cube•5 months agoProtalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
Categories: Yahoo FinanceGet free summary analysis Protalix Biotherapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Protalix Biotherapeutics, Inc. – Amicus Therapeutics, Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Neurocrine Biosciences, Inc. and Aviragen Therapeutics Inc (FOLD-US, PFE-US, TEVA-US, NBIX-US and AVIR-US) ... Read more (Read more...)
- ACCESSWIRE•5 months ago
Corporate News Blog - Protalix BioTherapeutics Gets Positive Opinion for Orphan Designation of PRX-102 for Treatment of Fabry Disease in EU
Desk Line-up: FibroGen Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 15, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Protalix BioTherapeutics, ...
